Nephron Clinical Practice
Original Paper
Involvement of Transglutaminase-2 in Pathological Changes in Renal DiseaseIkee R.a, b · Kobayashi S.b · Hemmi N.a · Saigusa T.a · Namikoshi T.a · Yamada M.a · Imakiire T.a · Kikuchi Y.a · Suzuki S.a · Miura S.aaSecond Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, and bDepartment of Nephrology and Kidney and Dialysis Center, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Subscribe
For eJournal Archive and eJournal Backfiles information please contact Karger service
Article / Publication Details
Received: May 16, 2006
Accepted: October 01, 2006
Published online: January 16, 2007
Issue release date: February 2007
Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 2
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Abstract
Background: Transglutaminase (Tg)-2 is shown to be related to renal fibrosis. However, its roles in human kidney disease have not been fully studied. Methods: Using immunohistochemistry, we examined Tg-2 expression in renal biopsy specimens from 22 patients with IgA nephropathy (IgAN) and correlated the intensity of Tg-2 staining with clinical and histopathological parameters. We compared the distribution and intensity of Tg-2 staining with those of transforming growth factor (TGF)-β staining. Results: In normal human kidneys, Tg-2 staining was not significant. In IgAN kidneys, glomerular Tg-2 staining correlated with serum creatinine (S-Cr), creatinine clearance (Ccr), urinary protein excretion, glomerular sclerosis, and mesangial cell proliferation. Tubulointerstitial Tg-2 correlated with S-Cr, Ccr, N-acetyl-β-glucosaminidase, urinary β2-microglobulin, and tubulointerstitial injuries. Tg-2 staining in the vicinity of vascular poles of glomeruli preceded the development of mesangial lesions, and was more remarkable in cases with renal impairment. The distribution and intensity of Tg-2 staining were not consistent with those of TGF-β staining. In glomerular crescents, Tg-2 staining was remarkable. Conclusion: The present study showed a correlation between Tg-2 expression and renal function and pathological changes. Tg-2 expression in the vicinity of vascular poles was notable because that may be an initial marker of glomerular injury.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Griffin M, Casadio R, Bergamini CM: Transglutaminase: nature’s glues. Biochem J 2002;368:377–396.
- Fesus L, Piacentini M: Transglutaminase-2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534–539.
- Thomazy V, Fesus L: Differential expression of transglutaminase in human cells: an immunohistochemical study. Cell Tissue Res 1989;255:215–224.
- Hirschberg R, Wang S: Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 2005;14:43–52.
- George MD, Vollberg TM, Floyd EE, Stein JP, Jetten AM: Regulation of transglutaminase type II by transforming factor-β1 in normal and transformed human epidermal keratinocytes. J Biol Chem 1990;265:11098–11104.
- Kojima S, Nara K, Rifkin DB: Requirement for transglutaminase in the activation of latent transforming factor-β in bovine endothelial cells. J Cell Biol 1993;121:439–448.
- Kikuchi Y, Kobayashi S, Hemmi N, et al: Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 2004;19:602–607.
- Ophascharoesuk V, Pippin JW, Gordon KL, Shankland SJ, Couser WG, Johnson RJ: Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int 1998;54:416–425.
-
Wada T, Hamakawa S, Hori Y, et al: Immunohistochemical localization of latent transforming growth factor-β binding protein in IgA nephropathy. Kidney Int 1997;52(suppl 63):S182–S184.
- Kliem V, Johnson RJ, Alpers CE, et al: Mechanisms involved in the pathogenesis of interstitial fibrosis in 5/6-nephrectomaized rats. Kidney Int 1996;49:666–678.
- Johnson TS, El-Koraie AF, Skill NJ, et al: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003;14:2052–2062.
- Skill NJ, Johnson TS, Coutts IG, et al: Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004;279:47754–47762.
- Douthwaite JA, Johnson TS, Haylor JL, Watson P, El Nahas AM: Effects of transforming growth factor-β1 on renal extracellular matrix components and their regulating proteins. J Am Soc Nephrol 1999;10:2109–2119.
- Howie AJ, Kizaki T, Beaman M, et al: Different types of segmental sclerosing glomerular lesions in six experimental models of proteinuria. J Pathol 1989;157:141–151.
- Kriz W, Hosser H, Hahnel B, Simons JL, Provoost AP: Development of vascular pole-associated glomerulosclerosis in the Fawn-hooded rat. J Am Soc Nephrol 1998;9:381–396.
- Harvey JM, Howie AJ, Lee SJ, et al: Renal biopsy findings in hypertensive patients with proteinuria. Lancet 1992;340:1435–1436.
- Howie AJ: Benign essential hypertension and kidney damage: a histopathologist’s view. J Hum Hypertens 1996;10:691–694.
- Osterby R, Asplund J, Bangstad HJ, et al: Glomerular volume and the vascular pole area in patients with insulin-dependent diabetes mellitus. Virchows Arch 1997;431:351–357.
-
Howie AJ: Pathology of minimal change nephropathy and segmental sclerosing glomerular disorders. Nephrol Dial Transplant 2003;18(suppl 6):vi33–vi38.
- Bowness JM, Folk JE, Timpl R: Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen. J Biol Chem 1987;262:1022–1024.
- Razzaque MS, Koji T, Taguchi T, Harada T, Nakane PK: In situ localization of type III and type IV collagen-expressing cells in human diabetic nephropathy. J Pathol 1994;174:131–138.
- Yoshioka K, Takemura T, Tohda M, et al: Glomerular localization of type III collagen in human kidney disease. Kidney Int 1989;35:1203–1211.
- Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995;96:953–964.
- Le Hir M, Keller C, Eschmann V, Hahnel B, Hosser H, Kriz W: Podocyte bridges between the tuft and Bowman’s capsule: an early event in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2001;12:2060–2071.
- Kanemoto K, Usui J, Tomari S, et al: Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis. Lab Invest 2003;83:1615–1625.
- Ng YY, Fan JM, Mu W, et al: Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol Dial Transplant 1999;14:2860–2872.
-
Fujigaki Y, Sun DF, Fujimoto T, et al: Mechanism and kinetics of Bowman’s epithelial-myofibroblast transdifferentiation in the formation of glomerular crescents. Nephron 2001;92:203–212.
External Resources
- Moeller MJ, Soofi A, Hartmann I, et al: Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004;15:61–67.
- Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacqout C: Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005;68:1109–1119.
-
Garcia GE, Xia Y, Harrison J, et al: Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am J Physiol 2003;162:1061–1073.
External Resources
- Isome M, Fujinaka H, Adhikary LP, et al: Important role for macrophages in induction of crescentic anti-GBM glomerulonephritis in WKY rats. Nephrol Dial Transplant 2004;19:2997–3004.
Article / Publication Details
Received: May 16, 2006
Accepted: October 01, 2006
Published online: January 16, 2007
Issue release date: February 2007
Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 2
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
